Drug Profile
Research programme: inflammatory bowel disease therapeutics - AbbVie/Synlogic
Alternative Names: Synthetic Biotic™ - SynlogicLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Synlogic
- Class Anti-inflammatories; Probiotics
- Mechanism of Action Bacteria replacements; Immunomodulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 21 May 2020 Research programme: inflammatory bowel disease therapeutics - AbbVie/Synlogic is available for licensing as of 21 May 2020. https://www.synlogictx.com/
- 21 May 2020 Synlogic terminates its collaboration with AbbVie for the development of synthetic biotic medicines for inflammatory bowel disease